Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liqi Shuxin Tablets is a Traditional Chinese Medicine (TCM) product manufactured by Jilin Fukang Pharmaceutical. It is formulated to regulate Qi circulation and soothe the heart, making it primarily indicated for cardiovascular disorders such as coronary heart disease and angina pectoris. The medication is typically used to treat symptoms including chest tightness, palpitations, and shortness of breath, which are attributed to Qi stagnation and blood stasis in TCM theory. The formulation consists of a complex blend of herbal ingredients, including *Cyperus rotundus*, *Citrus aurantium*, and *Ligusticum chuanxiong*, which are traditionally recognized for their analgesic and circulation-promoting properties. It is administered orally and is currently approved and marketed in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liqi shuxin tablets.